PhRMA pushes for 12-year drug exclusivity in TPP

10/10/2013 | Hill, The

An Obama administration proposal to reduce the number of years that drugmakers have exclusive rights to biologic drugs could be pre-empted by the Trans-Pacific Partnership's proposed timeline of 12 years. The Pharmaceutical Research and Manufacturers of America is pushing for 12-year exclusivity, saying that it is necessary for drugmakers to yield returns on their investments in research and development. "You won't have the new drugs unless you have the 12 years," PhRMA spokesman Mark Grayson said. "You need to give the people the incentive to develop."

View Full Article in:

Hill, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC